Loading
Latest filing published 02 Apr 2026 for Innovent Biologics, Inc..
No signal scores available.
Not enough history yet: 0 closed purchases, at least 2 are needed.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Hsu Joyce I-Yin is a declared insider of Innovent Biologics, Inc. (chief executive), with filings sourced from HKEX. In total, 9 filings cover trades dated from 15 April 2020 to 30 March 2026.
On the open market, the record shows 8 purchases and 1 sale. The totals do not cover 9 filings with an undisclosed amount. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. In 2026 alone, the filings show 1 purchase and no sales.
Most recently, on 2 April 2026, the filings show an open-market purchase in Innovent Biologics, Inc. Between a trade and the moment it shows up on HKEX, the median delay is 5 days. Until a filing is published, the market cannot know about the trade. This summary is built from HKEX disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
1 of 1 declaration